The Food and Drug Administration (FDA) has had a busy week. The FDA has approved Consertatm--a new form of a commonly used drug for attention deficit hyperactivity disorder that may help keep school-aged children from having to take the medication at school. The administration has also approved a new cream that helps to inibit the growth of unwanted facial hair. Millions of women are expected to be interested in Vaniqatm. Vidyya knows you're busy, so we've included the package insert information in today's issue. Both Conserta and Vaniqa are expected to be available to physicians and pharmacists by the first week of September.
A new antidiabetic drug will hit the shelves next week. The FDA has approved the Bristol Myers Squibb drug, Glucovance. Glucovance is a combination of two widely used medications, glyburide and Glucophage. The medication can be used as either a first- or second-line therapy for type II diabetes.
This Vidyya concludes with a review of a product designed to help busy professionals manage the task of educating their patients about common medications and their safe use. The product, a three-ring binder plus disk or CD-ROM includes easy to use handouts and guides that can be customized for individual use.
The articles in today's Vidyya are:
As always, we hope you enjoy the issue.